血肿扩大预测评分的独立验证:无对比剂评分与点征准确性相当
本研究为PREDICT队列的回顾性分析,旨在外部验证18分制无对比剂血肿扩大预测(HEP)评分,并与CTA点征比较诊断能力。共纳入292例急性脑出血患者,主要终点为血肿显著扩大(≥6 mL或≥33%),发生于94例(32%)。HEP评分与显著扩大独立相关(aOR 1.14,95%CI 1.01-1.30),AUC为0.64(95%CI 0.57-0.71),Youden法最佳截断值为4分;HEP≥4分(n=100)的敏感性49%、特异性73%、PPV 46%、NPV 75%,与点征(n=82,敏感性49%、特异性81%、PPV 55%、NPV 76%)的诊断特征相似。作者认为无对比剂预测工具可能在未来脑出血试验的患者招募中发挥作用。
要点
- HEP评分(18分制,无对比剂)与血肿显著扩大(≥6 mL或≥33%)独立相关:aOR 1.14(95%CI 1.01-1.30)。
- HEP评分预测显著扩大的AUC为0.64(95%CI 0.57-0.71),Youden法最佳截断值为4分。
- HEP≥4分(n=100)敏感性49%、特异性73%、PPV 46%、NPV 75%,aOR 1.99(95%CI 1.09-3.64)。
- CTA点征(n=82)敏感性49%、特异性81%、PPV 55%、NPV 76%,aOR 2.95(95%CI 1.61-5.42),诊断特征与HEP≥4分相似。
- HEP评分越高PPV越高,但以敏感性降低为代价。
适用人群与场景
- 急性脑出血(ICH)患者,来自PREDICT队列研究的外部验证人群,共292例纳入主要分析。
- 适用于无法接受静脉对比剂或所在医院系统未配备CTA技术的患者(原文背景中提及)。
诊断标准与关键阈值
- HEP评分:18分制无对比剂预测量表。
- 血肿显著扩大定义:血肿体积增加≥6 mL或≥33%。
- Youden法显示HEP评分最佳截断值为4分;HEP≥4分预测显著扩大。
研究设计与关键结果
- 研究类型:PREDICT队列研究的回顾性分析,外部验证HEP评分并与CTA点征比较诊断能力。
- 样本量:292例纳入主要分析;血肿扩大≥6 mL或≥33%发生于94例(32%)。
- HEP评分与显著扩大相关:aOR 1.14(95%CI 1.01-1.30)。
- ROC曲线:HEP评分预测显著扩大的AUC为0.64(95%CI 0.57-0.71)。
- HEP≥4分(n=100):敏感性49%、特异性73%、PPV 46%、NPV 75%,aOR 1.99(95%CI 1.09-3.64)。
- CTA点征(n=82):敏感性49%、特异性81%、PPV 55%、NPV 76%,aOR 2.95(95%CI 1.61-5.42)。
- HEP评分越高PPV越高,但敏感性降低。
- 作者结论:HEP评分可预测显著扩大(≥6 mL或≥33%),诊断准确性与点征相当;无对比剂预测工具可能在未来脑出血试验患者招募中发挥作用。
证据类型、等级与局限
- 证据类型:基于PREDICT队列研究的回顾性分析(外部验证)。
- 局限:原文未报告局限性
对床旁实践的改变
- 对于无法接受静脉对比剂或所在医院无CTA设备的急性脑出血患者,HEP评分可作为无对比剂的血肿扩大预测工具,其诊断准确性与CTA点征相似。
- HEP≥4分提示血肿显著扩大风险较高(aOR 1.99,95%CI 1.09-3.64),但敏感性仅49%,阴性结果不能排除扩大风险(NPV 75%)。
- 作者认为无对比剂预测工具可能在未来脑出血试验的患者招募中发挥作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: The computed tomography angiography (CTA) spot sign is widely used to assess the risk of hematoma expansion following acute intracerebral hemorrhage (ICH). However, not all patients can receive intravenous contrast nor are all hospital systems equipped with this technology. We aimed to independently validate the Hematoma Expansion Prediction (HEP) Score, an 18-point non-contrast prediction scale, in an external cohort and compare its diagnostic capability to the CTA spot sign.
METHODS: We performed a retrospective analysis of the predicting hematoma growth and outcome in intracerebral hemorrhage using contrast bolus CT (PREDICT) Cohort Study. Primary outcome was significant hematoma expansion (≥ 6 mL or ≥ 33%). We generated a receiver operating characteristic (ROC) curve comparing the HEP score to significant expansion. We calculated sensitivity, specificity, positive and negative predictive values (PPV/NPV) for each score point. We determined independent predictors of significant hematoma expansion via logistic regression.
RESULTS: A total of 292 patients were included in primary analysis. Hematoma growth of ≥ 6 mL or ≥ 33% occurred in 94 patients (32%). The HEP score was associated with significant expansion (adjusted odds ratio [aOR] 1.14, 95% confidence interval [CI] 1.01-1.30). ROC curves comparing HEP score to significant expansion had an area under the curve of 0.64 (95% CI 0.57-0.71). Youden's method showed an optimum score of 4. HEP Scores ≥ 4 (n = 100, sensitivity 49%, specificity 73%, PPV 46%, NPV 75%, aOR 1.99, 95% CI 1.09-3.64) accurately predicted significant expansion. PPV increased with higher HEP scores, but at the cost of lower sensitivity. The diagnostic characteristics of the spot sign (n = 82, Sensitivity 49%, Specificity 81%, PPV 55%, NPV 76%, aOR 2.95, 95% CI 1.61-5.42) were similar to HEP scores ≥ 4.
CONCLUSION: The HEP score is predictive of significant expansion (≥ 6 mL or ≥ 33%) and is comparable to the spot sign in diagnostic accuracy. Non-contrast prediction tools may have a potential role in the recruitment of patients in future intracerebral hemorrhage trials.
参考来源
- Yogendrakumar V, Ramsay T, Fergusson DA, et al. Independent Validation of the Hematoma Expansion Prediction Score: A Non-contrast Score Equivalent in Accuracy to the Spot Sign. Neurocrit Care. 2019. PMID: 31123995. doi:10.1007/s12028-019-00740-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。